NCT03926988RecruitingNot Applicable
A Prospective, Open-Label, Multi-Center, Registry Designed to Assess the Safety, Performance and Efficacy of the NeVa Stent Retriever in the Treatment of Large Vessel Occlusion Strokes
Vesalio1 site in 1 country400 target enrollmentStarted: April 1, 2019Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 400
- Locations
- 1
- Primary Endpoint
- Recanalization rate of occluded target vessel
Study Overview
Brief Summary
A prospective, open label, 90-day study designed to assess the safety, performance and efficacy of thrombus removal in subjects presenting with acute ischemic stroke with the NeVa stent retrievers.
Detailed Description
This is a prospective, open label, multi-center registry designed to assess the safety, performance and efficacy of the NeVa stent retriever in the treatment of large vessel occlusion strokes. Up to 400 subjects at up 20 sites will participate in the study.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Only subjects already treated with the NeVa devices can be considered for enrollment.
- •Clinical signs and symptoms consistent with the diagnosis of an acute ischemic stroke, and subject belongs to one of the following subgroups:
- •Subject has failed IV t-PA therapy
- •Subject is contraindicated for IV t-PA administration
- •NIHSS score ≥ 6
- •Pre-stroke mRS score of ≤ 1
- •Intracranial arterial occlusion of the distal intracranial carotid artery or middle cerebral artery (M1/M2), anterior cerebral artery (ACA), posterior cerebral artery (PCA), basilar artery, or vertebral artery demonstrated with DSA.
- •Thrombectomy procedure can be initiated within 24 hours from symptom onset (defined as time last known well [TLKW])
- •Imaging Inclusion Criteria:
- •Non-Contrast CT Selection (if CT Perfusion or MRI not utilized): ASPECTS 6-10 if treatment started 0-6 hours from TLKW ASPECTS 8-10 if treatment started 6-24 hours from TLKW
- •CT Perfusion core ≤50 cc
- •MRI DWI core ≤50 cc
- •Subject or legal representative is able and willing to give informed consent within 48 hours after the intervention.
Exclusion Criteria
- •Pre-existing medical neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia with prescribed anti-cholinesterase inhibitor (e.g. Aricept).
- •Cardiopulmonary resuscitation, significant cardiac arrhythmia, evidence of ongoing myocardial infarction, concern for pre- treatment pulmonary aspiration.
- •Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories
- •Cerebral vasculitis
- •History of severe allergy to contrast medium.
- •Known allergy to NeVa materials (nitinol, stainless steel)
- •Suspicion of aortic dissection, septic embolus, or bacterial endocarditis
- •Systemic infection
- •Significant mass effect with midline shift
- •Evidence of intracranial tumor (except small meningioma)
- •Inability to deploy NeVA device for at least one pass for any other reason
- •Life expectancy less than 6 months
- •Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the subject if an endovascular procedure was performed.
Outcomes
Primary Outcomes
Recanalization rate of occluded target vessel
Time Frame: post-procedure day 0
Recanalization rate of occluded target vessel (defined by an eTICI score ≥ 2b) following three or less passes using the NeVa device(s).
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Not Applicable
The Vesalio NeVa Stent Retriever Study for Treatment of Large Vessel Occlusion StrokesAcute Ischemic StrokeNCT03927001Vesalio150
Active, not recruiting
Not Applicable
The Vesalio NeVa Stent Retriever Study for Treatment of Large Vessel Occlusion Strokes: CLEAR StudyAcute Ischemic StrokeNCT04514562Vesalio120
Completed
Not Applicable
StimRouter Registry Clinical ProtocolChronic PainNervous System DiseasesPeripheral Nervous System DiseasesPeripheral Nervous System ProblemPeripheral Nerve InjuriesPeripheral NervousPeripheral NeuropathyNCT03913689Bioness Inc62
Recruiting
Phase 2
The Safety and Efficacy of Rapamycin on Communicating Hydrocephalus Secondary to Intraventricular HemorrhageCommunicating HydrocephalusCerebral Intraventricular HemorrhageSecondary Normal Pressure HydrocephalusPost Hemorrhagic HydrocephalusNCT06563817Beijing Tiantan Hospital53
Completed
Phase 4
A study to evaluate the efficacy and safety of vestige spirulina capsules for the immunity in healthy patients.CTRI/2022/09/045585Vestige Marketing Pvt Ltd50